Johnson & Johnson Shares Dip 2.3% Despite Positive News

Analysts remain cautious on the stock despite recent FDA approvals and pipeline progress.

Mar. 5, 2026 at 10:33pm

Got story updates? Submit your updates here. ›

Johnson & Johnson's (NYSE:JNJ) share price declined 2.3% on Thursday, trading as low as $235.93 before closing at $239.65. The drop came despite several positive developments for the company, including FDA approvals for new cancer treatments and progress on its drug pipeline.

Why it matters

Johnson & Johnson is a bellwether stock in the healthcare and pharmaceutical sectors, so its performance is closely watched by investors. The stock's decline despite the positive news highlights the cautious sentiment among analysts, who see modest upside potential despite the company's recent advancements.

The details

The key news impacting Johnson & Johnson this week includes FDA approval for TECVAYLI plus DARZALEX FASPRO for relapsed/refractory multiple myeloma, the launch of a direct-to-consumer sales website in the U.S., and progress on the company's pipeline drug nipocalimab. However, an ongoing legal challenge from Bayer over product claims has introduced litigation risk that is weighing on sentiment.

  • Johnson & Johnson's share price declined 2.3% on Thursday, March 5, 2026.

The players

Johnson & Johnson

A multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures, and markets a broad range of pharmaceutical, medical device, and consumer health products.

Bayer

A German multinational pharmaceutical and life sciences company that is engaged in a legal challenge with Johnson & Johnson over product claims.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.